Sebi imposes Rs 22 lakh fine on Trimurti Drugs' promoters
Advertisement
New Delhi: Markets regulator Sebi slapped fine of Rs 22 lakh on 13 promoters of Trimurti Drugs and Pharmaceuticals Ltd (TDPL) for their failure to make public announcement regarding acquisition of the company's shares.
A Sebi-conducted probe found that TDPL Healthcare (India) Ltd, promoter entity of Trimurti Drugs, along with the persons acting in concerts (PACs) had acquired 22.25 lakh shares or 3.3 per cent stake of Trimurti Drugs on January 22, 2010, through bulk deal.
A Sebi-conducted probe found that TDPL Healthcare (India) Ltd, promoter entity of Trimurti Drugs, along with the persons acting in concerts (PACs) had acquired 22.25 lakh shares or 3.3 per cent stake of Trimurti Drugs on January 22, 2010, through bulk deal.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.